Novartis AG ADR (NVS) Social Stream
NOVARTIS AG (NVS) Price Targets From Analysts
Use the tables below to see what analysts covering NOVARTIS AG think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-27 | 7 | $108 | $100 | $104.333 | $85.47 | 22.07% |
| 2022-01-17 | 8 | $105 | $100 | $102.666 | $85.47 | 20.12% |
| 2022-03-08 | 7 | $105 | $100 | $103 | $85.47 | 20.51% |
| 2022-04-13 | 6 | $105 | $100 | $103 | $85.47 | 20.51% |
| 2022-05-16 | 6 | $106 | $100 | $103.666 | $85.47 | 21.29% |
| 2022-08-26 | 6 | $105 | $97 | $101.666 | $85.47 | 18.95% |
| 2022-09-27 | 7 | $105 | $97 | $101.666 | $85.47 | 18.95% |
| 2022-10-25 | 7 | $105 | $97 | $101 | $85.47 | 18.17% |
| 2022-11-21 | 7 | $105 | $92 | $99.333 | $85.47 | 16.22% |
| 2022-12-05 | 7 | $105 | $101 | $102.666 | $85.47 | 20.12% |
| 2022-12-20 | 7 | $107 | $102 | $104.666 | $85.47 | 22.46% |
| 2023-01-16 | 7 | $108 | $102 | $105 | $85.47 | 22.85% |
| 2023-02-02 | 8 | $108 | $102 | $105 | $85.47 | 22.85% |
The Trend in the Analyst Price Target
NVS's average price target has moved down $0.73 over the prior 29 months.
Over the past 51 weeks, NVS's average upside potential has been 22.01%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-08-26 | 6 | 105 | 97 | 101.666 | 82.68 | 22.96% |
| 2022-09-10 | 7 | 105 | 97 | 101.666 | 82.60 | 23.08% |
| 2022-10-25 | 7 | 105 | 97 | 101.000 | 78.51 | 28.65% |
| 2023-01-16 | 7 | 108 | 102 | 105.000 | 91.06 | 15.31% |
| 2023-01-26 | 8 | 108 | 102 | 105.000 | 89.84 | 16.87% |
NVS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2 | 4 | 0 | 4 | 0 | 0 | 8 |
The Trend in the Broker Recommendations
Over the past 29 months, NVS's average broker recommendation rating worsened by 0.14.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for NVS as an investment opportunity.
- To contextualize these metrics, consider that out of all US stocks, NOVARTIS AG's variance in analysts' estimates is lower than 7.48% of them.
- In the context of stocks in the mega market cap category, NOVARTIS AG's number of analysts covering the stock is higher than 57.38% of them.
- NVS has a greater average analyst price target than 1283.59% of Pharmaceutical Products stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, NOVARTIS AG's upside potential (average analyst target price relative to current price) is higher than 274.71% of them.
Stocks similar to NOVARTIS AG in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ABBV, MRK, and JNJ.
View All Top Stocks by Price Target
Is NVS a Buy, Hold or Sell? See the POWR Ratings now!